(Q33884433)

29 July 2017

1 reference

title

SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression (English)

1 reference

29 July 2017

J M Kent

1

1 reference

PubMed ID

10752718

29 July 2017

language of work or name

English

0 references

publication date

1 March 2000

1 reference

29 July 2017

1 reference

29 July 2017

355

1 reference

29 July 2017

911-918

1 reference

29 July 2017

9207

1 reference

SSRIs versus tricyclic antidepressants in depressed inpatients: A meta-analysis of efficacy and tolerability

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Effects of antidepressant drugs on different receptors in the brain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, org 3770 and its enantiomers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Nefazodone and imipramine in major depression: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Controlled comparison of nefazodone and amitriptyline in major depressive inpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

A double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

A risk-benefit assessment of mirtazapine in the treatment of depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

A double-blind placebo-controlled study of Org 3770 in depressed outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Nefazodone-induced liver failure: report of three cases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Safety of mirtazapine: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Coadministration of nefazodone and benzodiazepines: I. Pharmacodynamic assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Coadministration of nefazodone and benzodiazepines: IV. A pharmacokinetic interaction study with lorazepam

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Drug and ethanol effects on the clinical test for drunkenness: single doses of ethanol, hypnotic drugs and antidepressant drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911381-3

7 January 2021

10.1016/S0140-6736(99)11381-3

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10752718